Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do you have a link to the interview?
Thanks
Still have many chances
Great news out tonight after hours
Not this morning
Oh my
Down to $7 on bad ZYNE 1 results
Fun right now
Apparently news is out
AH trading looking good
These guys were mentioned in the Philly Business Journal not too long ago regarding the possibility of FDA priority review vouchers which could potentially be worth a lot of money if they got approval. Not sure how true.
But this could be a steal at these levels.
Who knows, but I like the risk/reward here.
Thoughts on move today ?
Good news released this morning
A strong buy here
Maybe u are right
Did anyone listen to call
Thoughts ?
I agree
It’s good not to get caught up in daily movements
That being said, disappointing price action as of late
My question is, if we do not meet primary endpoints but meet secondary for a certain populations, etc
how will the stock price react
Do we see a sell off on the headline ?? and to what extent?
I didn’t realize that Avastin was officially approved for rGBM
It was under a conditional approval
I don’t think this works against VBL
Thoughts?
Not sure about the tricks
And the FDA should help
Nothing out there
Updated report issued by HC
Vascular Biogenics, Ltd. (VBLT) / Swayampakula Ramakanth, Ph.D.
Price: $6.15; Market Cap (MM): $183; Rating: Buy; Target Price: $11.00
GLOBE Readout in March Could Herald a New Standard in GBM Therapy; Reiterate Buy Click here for full report
Topline results from the pivotal Phase 3 GLOBE study expected next month. With topline results from the GLOBE study expected in the near term, we present the potential scenarios and our thoughts on the study. Recall, the Phase 3 GLOBE study is a 256-patient randomized, controlled study that is evaluating the combination of VB-111 (ofranergene obadenovec) with Avastin (bevacizumab, marketed by Roche (RHHBY; not rated)) against Avastin alone in the treatment of recurrent GBM (rGBM). The study completed patient enrollment in December 2016 and readout of topline results is scheduled to occur after 75% of patient events, which we expect to happen in the second half of March. The primary outcome measure of the study is overall survival (OS). In the previous Phase 2 study, patients treated with VB-111 plus Avastin achieved a median OS of 15 months, compared to historical OS of 9-12 months for Avastin alone. We believe that if the VB-111 cohort can replicate the success of Phase 2 study and achieve a similar OS, then the VB-111 plus Avastin combination could become the new standard of care for this difficult to treat indication. Management has indicated that beyond topline OS, other predefined survival endpoints include: 1) OS stratified by the size of the tumor (medium > 15 ml; large > 32 ml); 2) OS at 12 months; and 3) OS for patients who survive at least 100 days (excluding rapid progressors). According to management, all predefined endpoints are included in the Special Protocol Assessment (SPA) that was reviewed by the FDA. Specifically, the last endpoint (OS for patients survived 100 days) was included under the rationale that it could take a considerable amount of time for the drug-induced immune response to reach its full-scale effect. Additional secondary endpoints of the GLOBE study include progression-free survival and tumor response (as measured by RANO criteria). Taken together, we have an optimistic view on the anticipated GLOBE results, and we believe that the inclusion of additional surrogate survival endpoints help mitigate downside risk, acting as a safety cushion for investors.
GLOBE study design helps to mitigate potential downside.
What to expect from VB-111 beyond GBM.
Valuation and risks.
.
Not trading well at all
But I still believe the threshold is low and for a percentage of the population this will show promising efficacy
A steal at these levels for any decent efficacy for the worst of the worst cancers
Good news here
I am not so sure this will be a binary event
Maybe efficacy will show for a certain population of patients
Thoughts?
No doubt
Going higher
Wow
What a visionary this guy was
He built an amazing company
Employed thousands across the world
The best casino operator ever
No doubt
If it goes on sale tomorrow I am in
Very sad ending on multiple fronts for Steve Wynn
Interesting article
Thanks for posting
Not sure why the stock is getting beat up today
Any thoughts ?
A steal at these levels !!
Major lieutenants to Wynn
This is not a one man operation
Macau is an ATM machine
Vegas and Macau need Wynn
What an overreaction !
Guilty by the WSJ until proven innocent
Unreal
Hard to believe this stock is not $4 or more per share
This is great news!!
Get out from under Braeburn
Nothing but disappointment there
With a different partner with Probuphine alone the market cap
should be in excess of $100 million
let alone the value ascribed for their other indications like Parkinson’s etc
Hear u
This is still an amazing buy at these levels
Go GALT!
Notwithstanding the SPA with the FDA, would they consider stopping the trial early for those not on VB111?
Hope you are right !!
This company is a steal at these levels if so
When is the meeting?
Totally agree
These are amazing additions to the Board of Directors
I would also think that these folks have a pretty good feel that VBL has something here after doing their due diligence
Doc
If you were new to the story, would you buy here ?
I agree
Things are looking good for positive results for this rGBM trial
Huge opportunity for Vb111 in combo therapy for numerous indications
and if it works with rGBM....wow
Thoughts as to why this is not trading well these levels now?
How great is NOG
Eggnog coming through for us longs over the Holiday Season
Still a steal at these levels!
Patience paying off here for sure
Thanks for posting
This stock is a steal at these levels !
Wow
Nice to see it holding over 7
Hoping we will see an ovarian announcement soon
I am glad we closed the week pre Christmas with a 7 number out front !
I remain optimistic for the balance of this year and hopefully for a great 2018 for the VBL longs
Happy Holidays to all !
I could not open ?
Is this old news that they are now releasing from the presentation for the first time?
Not sure
No way would I sell this stock here
Maybe trim a bit if you are already in
But this market cap is ridiculous
Story just being picked up by investors
Good question ?
Maybe it has something to do with the special protocol assessment?
Not sure
Where is the press release where NVCR announced the stopping of the trial early?
Was looking for it but could not find it
Thanks
Agreed
How do u read that?
Looks like tomorrow am
Thoughts ?
What a call on egg nog by MJW
Still a buy at these levels !!
GREAT DAY FOR US LONGS!
Nice move
Hope it continues